# Patient-Reported Outcome Of Facial Erythema (PROOF)

> **NCT01885000** · PHASE3 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 92 (actual)

## Conditions studied

- Rosacea
- Erythema

## Interventions

- **DRUG:** Brimonidine tartrate was applied cutaneously once daily for 8 days.
- **DRUG:** Brimonidine tartrate vehicle was applied cutaneously once daily for 8 days.

## Key facts

- **NCT ID:** NCT01885000
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-01
- **Primary completion:** 2013-11-14
- **Final completion:** 2013-11-14
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2021-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01885000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01885000, "Patient-Reported Outcome Of Facial Erythema (PROOF)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01885000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*